阿达木单抗重编程M1巨噬细胞抑制Behçet葡萄膜炎与VKH综合征的Th1/Th17反应
该研究探讨阿达木单抗对Behçet葡萄膜炎(BU)和Vogt-Koyanagi-Harada(VKH)综合征患者单核细胞来源巨噬细胞极化和CD4+ T细胞反应的影响及机制。体外实验显示阿达木单抗选择性抑制M1极化及TNF-α、IL-1β、IL-6、IL-12产生,重编程的M1巨噬细胞促进CD4+ T细胞凋亡并抑制Th1/Th17反应,但阿达木单抗不直接影响T细胞。多组学揭示BU中金属硫蛋白成员(MT1H、MT1G等)和VKH中SLC39A8表达下调的疾病特异性机制,EAU模型验证阿达木单抗逆转脾脏CD80+巨噬细胞和Th1/Th17细胞频率增加并与葡萄膜炎缓解相关。
要点
- 阿达木单抗选择性抑制BU和VKH患者M1巨噬细胞极化及TNF-α、IL-1β、IL-6、IL-12产生。
- 重编程的M1巨噬细胞促进CD4+ T细胞凋亡并抑制Th1/Th17反应,阿达木单抗不直接影响T细胞。
- BU中金属硫蛋白成员(MT1H、MT1G等)和VKH中SLC39A8表达显著下调,提示疾病特异性机制。
核心结论
- 阿达木单抗通过靶向BU和VKH中的不同蛋白调节巨噬细胞极化,从而减弱T细胞介导的炎症。
- 该研究为葡萄膜炎的精准免疫治疗提供了新见解。
研究设计与样本
- 对活动性BU患者(n=43)和VKH患者(n=35)的单核细胞来源巨噬细胞和CD4+ T细胞进行体外分析。
- 使用实验性自身免疫性葡萄膜炎(EAU)模型进行体内实验。
- 采用流式细胞术和酶联免疫吸附试验评估巨噬细胞极化和细胞因子产生。
- 使用健康供者CD4+ T细胞的共培养系统评估免疫调节级联反应。
- 通过整合转录组学和蛋白质组学分析研究疾病特异性机制,并用实时定量PCR和蛋白质印迹验证。
主要发现
- BU和VKH患者中促炎M1巨噬细胞极化显著增强。
- 阿达木单抗选择性抑制M1极化及TNF-α、IL-1β、IL-6、IL-12的产生。
- 阿达木单抗重编程的M1巨噬细胞促进CD4+ T细胞凋亡并抑制Th1/Th17反应,但阿达木单抗不直接影响T细胞。
- 多组学分析显示BU中金属硫蛋白成员(MT1H、MT1G、MT1A、MT1F、MT1E、MT1X、MT2A)表达显著下调,VKH中SLC39A8表达显著下调。
- EAU模型中阿达木单抗治疗逆转脾脏CD80+巨噬细胞和Th1/Th17细胞频率增加,并与葡萄膜炎缓解相关。
临床怎么用
- 阿达木单抗可能通过调节巨噬细胞极化而非直接作用于T细胞来减轻葡萄膜炎炎症。
- BU和VKH的疾病特异性分子靶点(金属硫蛋白成员和SLC39A8)可能为精准免疫治疗提供方向。
局限性
- 研究纳入的活动性BU和VKH患者样本量有限(分别为43例和35例)。
- 机制发现主要基于体外实验和EAU模型,需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the effects and underlying mechanisms of adalimumab on monocyte-derived macrophage polarization and CD4+ T cell responses in patients with Behçet's uveitis (BU) or Vogt-Koyanagi-Harada (VKH) syndrome. METHODS: Ex vivo analyses were performed on monocyte-derived macrophages and CD4+ T cells from patients with active BU (n = 43) and VKH (n = 35). In vivo experiments were performed using an experimental autoimmune uveitis (EAU) model. The effects of adalimumab on macrophage polarization and cytokine production were assessed using flow cytometry and enzyme-linked immunosorbent assay, respectively. The underlying adalimumab-induced immunomodulatory cascade was evaluated using coculture systems with healthy donor CD4⁺ T cells. Disease-specific mechanisms were investigated through integrated transcriptomic and proteomic profiling and validated by real-time quantitative polymerase chain reaction and western blot. RESULTS: Proinflammatory M1 macrophage polarization was significantly enhanced in patients with BU and VKH. Adalimumab selectively suppressed M1 polarization and the production of tumor necrosis factor-alpha, IL-1β, IL-6, and IL-12. These adalimumab-reprogrammed M1 macrophages promoted CD4+ T cell apoptosis and inhibited Th1/Th17 responses. However, adalimumab did not directly affect T cells. Multi-omics analysis and validation experiments revealed disease-specific mechanisms, notably the significant downregulation of the expression of metallothionein members, including MT1H, MT1G, MT1A, MT1F, MT1E, MT1X, and MT2A, in BU and that of SLC39A8 in VKH. Furthermore, adalimumab therapy reversed the increased frequencies of CD80+ macrophages and Th1/Th17 cells in the spleen and in association with remission of uveitis in the EAU model. CONCLUSIONS: Adalimumab modulates macrophage polarization to attenuate T cell-mediated inflammation by targeting different proteins in BU and VKH, providing novel insights for precision immunotherapy in uveitis.
引用
- Zhu Y, Yu Q, Ma Y, et al. Adalimumab Reprograms M1 Macrophages to Attenuate Th1/Th17 Responses in Behçet's Uveitis and Vogt-Koyanagi-Harada Syndrome. Invest Ophthalmol Vis Sci. 2026. PMID: 42227805. doi:10.1167/iovs.67.6.4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。